Compare Dyne Therapeutics Inc. Common Stock (DYN) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs T-Mobile Us Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while T-Mobile Us Inc trades at $159.78 (market cap $169.26B). The key difference: T-Mobile Us Inc is far larger — about 60.2× Dyne Therapeutics Inc. Common Stock's market cap, and T-Mobile Us Inc pays a 2.97% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and T-Mobile Us Inc for 84 Days on average.
| DYN | TMUS | |
|---|---|---|
Market Cap | $2.81B | $169.26B |
Volume | 2,195,902 | 7,268,670 |
Sector | Health | Media |
52-Week High | $26.78 | $230.06 |
52-Week Low | $14.60 | $148.58 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $2.13B | $285.87B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
T-Mobile US (TMUS) trades at $153.73, up 1.22% with a bearish technical outlook despite strong fundamentals. The company reported robust Q2 2026 earnings beat ($2.99 vs. $2.59 expected) and maintains solid profitability with 62.19% gross margins. Recent developments include a 15% dividend increase and AI-powered 5G network enhancements. Analyst consensus remains strongly bullish with 81% buy ratings and a $221.75 price target, representing 44% upside potential.
TMUS offers compelling value with reasonable valuation multiples (P/E 16.51, EV/EBITDA 8.86) and strong cash flow generation. Key risks include $84.6 billion debt load, competitive pressures from Verizon and AT&T, and potential margin compression. The stock presents a growth-at-reasonable-price opportunity for investors comfortable with telecommunications sector dynamics and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
